The purpose is to determine whether long‑term use of Admilparant is safe and does not lead to serious side effects.

Participants will take one tablet each day for several years while doctors perform regular check‑ups. At each visit routine blood work, a quick heart test called an ECG that records the heart’s electrical activity, and measurements of blood pressure and heart rate are done. The study records any side effects, changes in test results, or reasons to stop the medication, and follows each person from the start until the study ends.

This clinical trial is focused on studying Type 1 Diabetes in adults who are also overweight or have obesity. The treatment being tested is called tirzepatide (also known by its code name LY3298176), which is given as a solution for injection using a pre-filled pen. The purpose of the study is to see if tirzepatide can help control blood sugar levels better than a placebo.

Participants in the study will receive either tirzepatide or a placebo once a week. The study will last for about 40 weeks. During this time, the effects of tirzepatide on blood sugar levels will be closely monitored. The study aims to determine if tirzepatide is more effective than a placebo in managing blood sugar levels in people with Type 1 Diabetes.

This study is important for understanding how tirzepatide can help people with Type 1 Diabetes who are also dealing with being overweight or obese. The results could provide valuable insights into new treatment options for better managing blood sugar levels in these individuals.

Participants in the study will receive Nemtabrutinib in the form of a tablet taken by mouth. The study is divided into two parts. In the first part, the focus is on understanding the safety and how well the body can tolerate Nemtabrutinib. In the second part, the study will look at how well the medication works in treating the different types of blood cancers mentioned. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Nemtabrutinib.

The study will take place over a period of time, with participants being monitored for any side effects and the effectiveness of the treatment. The goal is to gather information that could help improve treatment options for people with these types of blood cancers. Participants will be closely observed by medical professionals throughout the study to ensure their safety and to collect valuable data on the medication’s impact.

The main goal is to see whether long‑term use of the medication is safe and whether it continues to provide clinical benefit for people with this condition. Participants will receive the study drug every day for several years and will attend regular clinic visits where they will be asked about any side effects, have simple physical tests such as walking speed measured with the 10MWT, and undergo breathing assessments using the FVC test, which checks how well the lungs can move air in and out while sitting. Blood samples will also be taken to monitor levels of serum CK, an enzyme that rises when muscle damage occurs.

During the study, researchers will track changes in muscle strength, walking ability, and breathing function from the start of the trial to its end. Any new health problems or worsening of existing symptoms will be recorded, and the overall safety of the medication will be closely monitored throughout the study period.

The purpose of the trial is to assess whether the combination of these two medicines works better than the usual care for people whose disease has come back after one to three prior treatments. Participants receive the study drugs for up to twelve treatment cycles, with regular clinic visits to monitor health, check for side effects, and evaluate how the disease is responding. The study is open‑label, so both the participants and the doctors know which medicines are being used, and it is a phase II trial, a stage that focuses on determining effectiveness and safety before larger studies are done.

The purpose of the trial is to determine whether MK-1045 can achieve a higher rate of complete remission (no detectable cancer) and improve overall survival (how long participants live) compared with blinatumomab. Participants will receive a series of treatment cycles lasting several weeks, during which doctors will monitor for adverse events (side effects) and check for minimal residual disease negativity (absence of tiny amounts of cancer cells). Some participants may later undergo allogeneic hematopoietic stem cell transplantation, a procedure that replaces diseased blood‑forming cells with healthy ones from a donor, if deemed appropriate by their physicians.

Participants are randomly assigned to receive either tablets containing 1800 mg of thiamine hydrochloride or matching placebo tablets for a period of four weeks. The trial is conducted in a double-blind manner, meaning that neither the participants nor the study staff know which tablets are being taken. Study visits include an initial assessment, regular check‑ins, and a final evaluation after the treatment period.

The purpose is to compare the effect of high dose thiamine with placebo on changes in fatigue as measured by the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional-Questionnaire global score from the start of the study to week 4.

The goal of the trial is to find out whether adding Venetoclax to the standard three‑drug mix can improve overall survival, which means living longer after the treatment starts.

In this phase 3 study, children are placed by chance into one of two groups: one group receives the three standard drugs, and the other group receives the same three drugs plus the oral Venetoclax. Treatment is given in cycles over several weeks, and the children are checked regularly to see how they are doing and to record any side effects. The study follows each participant for a period of time to see how long they live and how they feel.

The main purpose of the trial is to keep participants who are still benefiting from the drug under medical supervision while safety is monitored. After joining, participants will continue to receive opnurasib on a regular schedule for as long as it remains helpful and tolerable. Visits will include simple check‑ups to record any side effects, any changes in dosage, and overall health. The study does not involve any additional invasive procedures beyond the usual care for this condition.

The purpose is to determine whether early vaccination changes how strong the immune protection is later, measured by the amount of neutralising antibodies against measles several years after the routine dose given at age 4. Children are followed for up to three years after that routine dose, and blood samples are tested using a plaque-reduction neutralisation test and also to assess levels of IgG, a protein that shows immune memory. The study follows each child through the early vaccination, the routine dose, and the later check‑ups without requiring special procedures beyond routine clinic visits.

On the day of surgery, the drug is given and then the patient undergoes either a minimally invasive robotic removal of the throat tumor using transoral robotic surgery or a removal of lymph nodes in the neck with neck dissection surgery. During the operation the surgeon watches the glowing signal and notes whether cancer is visible. After removal, the tissue is examined under a microscope to confirm whether the glowing areas matched the cancer. The study follows each participant for a short period after surgery to collect the imaging and pathology results.

The purpose of the trial is to compare how well the new medicine works against the standard treatment in shrinking tumors and helping patients live longer. Participants will be randomly assigned to one of the two treatment arms and will receive the assigned therapy in repeated cycles every few weeks. Throughout the study, doctors will perform regular safety checks, blood tests, and imaging scans to see how the disease responds, and they will record any side effects that occur.

The purpose of the study is to evaluate whether the new medicine can lower the number of treated bleeds compared with standard therapy. Participants will be assigned to receive either the new medicine or the standard factor VIII for about six months, attending regular visits where any bleeding events are recorded, quality‑of‑life questionnaires are completed, and safety checks such as blood tests for antibodies or reactions at the injection site are performed. The trial will monitor how often injections are needed, the amount of medicine used, and any side effects that arise during the treatment period.

During the study, participants will be assigned to receive either depemokimab or a placebo through a subcutaneous injection, which is a shot given just under the skin. The study is designed so that neither the participants nor the researchers know which treatment is being administered. This approach helps ensure that the results are as accurate as possible.

The purpose of the trial is to determine whether MK-8748 is at least as effective as aflibercept in preserving or improving vision. Participants will receive a series of injections into the eye over the course of about one year, with regular visits for eye checks, vision testing, and imaging that may involve the fluorescein dye.

Vision is measured using best-corrected visual acuity, which is the sharpest vision possible with the best glasses or contacts, and the results are recorded as letters on an ETDRS chart, a standard eye‑test chart. Throughout the study, doctors will monitor participants for any side effects or safety concerns.

Participants are randomly assigned to receive either a daily oral pill such as edoxaban or apixaban, an injectable medicine such as dalteparin, tinzaparin, enoxaparin, or rivaroxaban, or a placebo that looks the same but contains no active drug. Over several months, they will have regular check‑ups that may include simple scans of the lungs to confirm whether the clot has changed, and they will complete questionnaires about their daily well‑being. The study does not require any special procedures beyond the usual care for cancer and clot management.

Participants in the study will be randomly assigned to receive either cabozantinib plus supportive care or just supportive care. The study will monitor the participants over a period to see how the treatment affects the progression of the disease. The trial will also assess the safety of cabozantinib and how the body processes the drug, which is known as pharmacokinetics. The study will involve regular check-ups and assessments to track the health and progress of the participants.

The trial aims to provide valuable information on whether cabozantinib can help improve the outcomes for young people with osteosarcoma. The study will last for several months, and participants will be closely monitored throughout the process to ensure their safety and to gather data on the effectiveness of the treatment. The results of this study could potentially lead to better treatment options for those affected by this challenging condition.

The purpose of the study is to understand how safe and tolerable the new treatment is for patients, as well as to see how well it works in reducing the size of the cancer. Participants in the study will receive the investigational treatment, and their response to the treatment will be monitored over time. The study will also look at how long any positive effects of the treatment last.

Throughout the study, researchers will keep track of any side effects experienced by participants and whether these side effects lead to stopping the treatment. The study aims to gather important information that could help in developing new treatment options for people with this type of cancer. The trial is expected to continue until early 2028.

The purpose of the study is to assess the safety and effectiveness of this stem cell treatment compared to a placebo. Participants in the study will receive an injection into their knee joint, either with the stem cell treatment or a placebo. The study will monitor knee symptoms and any side effects over a period of time to determine how well the treatment works and how safe it is for patients.

Throughout the study, participants will be asked to keep a diary of their knee pain and other symptoms. They will also undergo various assessments, including the Knee Injury and Osteoarthritis Score (KOOS) and MRI scans, to evaluate changes in their knee condition. The study aims to provide valuable insights into the potential benefits of using stem cells for treating knee osteoarthritis.

The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 capsules or a placebo, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a double-blind study. The study will take place over a period of time, during which participants will be monitored for changes in their symptoms and any side effects they may experience.

Throughout the study, participants will be asked to take the medication orally, in capsule form, and will be regularly assessed by healthcare professionals. The study aims to provide valuable information on whether AVP-786 can be a beneficial treatment option for managing agitation in patients with Alzheimer’s disease. The results will help determine if this medication can improve the quality of life for those affected by this condition.

The purpose of the study is to see how well Nemtabrutinib works compared to the other two treatments in people who have not yet received treatment for their CLL or SLL. Participants will be randomly assigned to receive either Nemtabrutinib or one of the other two medications chosen by the study doctor. The study will last for a period of up to 108 weeks, during which participants will take the medication daily and attend regular check-ups to monitor their health and the progress of the disease.

Throughout the study, doctors will assess how the disease responds to the treatment and how long participants remain free from disease progression. They will also monitor overall survival and any side effects experienced by participants. The study aims to provide valuable information on the effectiveness and safety of Nemtabrutinib compared to the current standard treatments for CLL and SLL.

Participants in the study will be randomly assigned to receive either Upadacitinib or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations. The study will last for a period of time, during which participants will take the medication orally in the form of a modified-release tablet. The goal is to observe any changes in the severity of eczema symptoms and overall skin condition over the course of the study.

Throughout the study, participants will be monitored for any improvements in their eczema symptoms, such as reduced itching and inflammation, as well as any potential side effects. The study aims to provide valuable information on whether Upadacitinib can be an effective treatment option for those suffering from moderate to severe eczema. By participating in this study, researchers hope to gain insights that could lead to better management and treatment options for individuals with this challenging skin condition.

The purpose of the study is to find out if using targeted oxygen therapy can reduce the risk of death within 30 days compared to standard care. Participants in the study will receive one of the oxygen therapies, and some may also receive medications like Berodual (containing fenoterol hydrobromide and ipratropium bromide), Salbutamol, or Medicinal Oxygen to help with breathing. These treatments are given through inhalation, which means they are breathed in using a device called a nebulizer or as a compressed gas.

The study will follow participants over a period to monitor their health outcomes, such as survival rates at different time points, the length of hospital stays, and the need for additional breathing support like non-invasive ventilation (NIV) or mechanical ventilation. The goal is to improve the care and outcomes for patients with AECOPD by determining the most effective oxygen therapy approach.

The purpose of the study is to learn about the safety of BIIB080 and whether it can improve symptoms in participants. Participants will receive the treatment through an injection into the spinal fluid, a method known as intrathecal use. The study will last for a period of 76 weeks, during which participants will be monitored for changes in their cognitive abilities and overall health. The study aims to understand how different doses of the treatment affect the symptoms of Alzheimer’s disease.

Throughout the study, participants will undergo various assessments to track their progress. These assessments include tests to measure memory and thinking skills, as well as monitoring for any side effects or adverse events. The study is designed to provide valuable information on the potential benefits and safety of BIIB080 for individuals with early stages of Alzheimer’s disease.

Participants in the study will receive either secukinumab or a placebo. The study will last for 24 weeks, during which the effects of the treatment on shoulder symptoms will be monitored. The main focus will be on changes in physical symptoms related to the shoulder, assessed at different points throughout the study. Participants will be asked to continue any existing treatments, such as non-steroidal anti-inflammatory drugs (NSAIDs) and physiotherapy, at a stable dosage and regimen.

The study will also involve monitoring the safety and tolerability of secukinumab, including any side effects or changes in laboratory results. Participants will have their progress evaluated through various assessments, including the Western Ontario Rotator Cuff Index (WORC) and the Patient-Reported Outcomes Measurement Information System (PROMIS). The study aims to provide valuable insights into the potential benefits of secukinumab for individuals with rotator cuff tendinopathy.

Participants in the study will receive either XTMAB-16 or a placebo, which looks like the treatment but does not contain the active ingredient. The study is divided into two parts. In the first part, the focus is on determining the safe dosage levels of XTMAB-16. In the second part, the study will assess how well XTMAB-16 works in reducing the use of corticosteroids. Throughout the study, participants will be monitored for any side effects and changes in their condition.

The study aims to find out if XTMAB-16 can help patients with pulmonary sarcoidosis by allowing them to reduce their reliance on corticosteroids, which can have significant side effects when used long-term. The trial will also gather information on how the body processes XTMAB-16 and its impact on various health markers. This research could lead to new treatment options for those living with this condition.

The purpose of the study is to assess the effectiveness and safety of OATD-01 over a 12-week period. Participants will be randomly assigned to receive either OATD-01 or a placebo, and neither the participants nor the researchers will know which treatment is being administered. Throughout the study, participants will undergo various assessments, including imaging tests like [18F]FDG PET/CT, to monitor changes in lung inflammation and overall health. The study aims to determine if OATD-01 can reduce the inflammation in the lungs and improve lung function and quality of life for those with active pulmonary sarcoidosis.

Participants will be closely monitored for any side effects or changes in their health during the study. The trial will also collect data on various health parameters, such as lung function tests and quality of life questionnaires, to evaluate the overall impact of the treatment. The study is expected to provide valuable insights into the potential benefits of OATD-01 for individuals with active pulmonary sarcoidosis.